Filing Details

Accession Number:
0000902664-18-002624
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-19 16:05:59
Reporting Period:
2018-06-15
Accepted Time:
2018-06-19 16:05:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
722830 Immunomedics Inc IMMU In Vitro & In Vivo Diagnostic Substances (2835) 611009366
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1633313 Venbio Select Advisor Llc 120 West 45Th Street
Suite 2802
New York NY 10036
Yes No Yes Yes
1701815 Behzad Aghazadeh C/O Venbio Select Advisor Llc
120 W. 45Th Street, 28Th Floor
New York NY 10036
Yes No Yes Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.01 Par Value Per Share Acquisiton 2018-06-15 200,000 $23.39 17,714,461 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Footnotes
  1. The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
  2. The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
  3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.32 to $23.4998 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein.